EUVIMEDEUVIMED entdecken
Crossref

Direct oral anticoagulants and warfarin safety in rural patients with obesity

Zachary R Caverley, Ross J Bindler, Pamela Soh, Sherri Mendelson

The American Journal of the Medical Sciences · 2023

DOI: 10.1016/j.amjms.2023.01.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of the Medical Sciences, 2023. Verfasst von Zachary R Caverley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Providence Oregon Cardiology Group, Astoria, OR, USA. Electronic address: Zachary.Caverley@providence.org. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Direct oral anticoagulants (DOACs) are often used in patients with atrial fibrillation or flutter instead of warfarin and although supporting evidence is limited, available studies suggest this may be an acceptable route of care. Our study assessed the question: are DOACs as effective and safe as warfarin in patients with atrial fibrillation and class III obesity specifically in a rural population? METHODS: A retrospective analysis was conducted by examining the first 6-12 months of therapy with a DOAC (apixaban or rivaroxaban) or warfarin in patients with weight >120kg or class III obesity. Events of interest, thrombosis and bleeding, were documented for analysis. The risk and odds of events of interest for both groups were calculated and compared. RESULTS: Characteristics of both arms were similar (DOAC n=42; warfarin n=43). A lack of thrombosis events limited efficacy analysis. A total of 22 bleeds occurred with 8 in patients prescribed a DOAC (7 minor; 1 major) and 14 in those prescribed warfarin (12 minor; 2 major). Weight in kg (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeHumansWarfarinAnticoagulantsRetrospective StudiesRural PopulationHemorrhageObesityAdministration, OralDabigatran

Stichwörter der Autor:innen

AnticoagulantsAtrial fibrillationFactor Xa inhibitorsObesityRural

Substanzen

WarfarinAnticoagulantsDabigatran

Autor:innen und Institutionen

  • Providence Oregon Cardiology Group, Astoria, OR, USA. Electronic address: Zachary.Caverley@providence.org.
  • Washington State University Spokane, College of Nursing and Elson S. Floyd College of Medicine, Spokane, WA, USA.
  • Providence Seaside Hospital, Seaside, OR, USA.
  • Providence Holy Cross Medical Center, Mission Hills, CA, USA.

Zitieren

APA

Caverley, Z. R., Bindler, R. J., Soh, P., & Mendelson, S. (2023). Direct oral anticoagulants and warfarin safety in rural patients with obesity. The American Journal of the Medical Sciences. https://doi.org/10.1016/j.amjms.2023.01.004

Vancouver

Caverley ZR, Bindler RJ, Soh P, Mendelson S. Direct oral anticoagulants and warfarin safety in rural patients with obesity. The American Journal of the Medical Sciences. 2023. doi:10.1016/j.amjms.2023.01.004

BibTeX
@article{Caverley2023,
  author = {Caverley, Zachary R and Bindler, Ross J and Soh, Pamela and Mendelson, Sherri},
  title = {Direct oral anticoagulants and warfarin safety in rural patients with obesity},
  journal = {The American Journal of the Medical Sciences},
  year = {2023},
  doi = {10.1016/j.amjms.2023.01.004}
}
Kostenlos starten →